{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:08:51Z","timestamp":1781719731516,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the utility of [<jats:sup>18<\/jats:sup>F]fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging ([<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup>) in patients with difficult-to-localize prolactinoma to inform clinical decision-making and (surgical) treatment planning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective cohort study of 17 consecutive patients with prolactinoma undergoing [<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup> between October 2020 and September 2022 for either (1) additional information in case of difficult-to-visualize remnants after prior transsphenoidal surgery (TSS), or pharmacological treatment, or (2) radiological diagnosis in absence of a (clear) adenoma on diagnostic\/post-treatment conventional MRI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup> identified a lesion in 14\/17 patients, yet failed to identify active lesions in 2 patients with negative conventional MRI despite prolactin\u2009&gt;\u20097.5 times upper limit of normal. [<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup> results were inconclusive in 1 patient due to diffuse tracer uptake 10 weeks post-surgery. [<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup> was completely concordant with a suspected lesion on conventional MRI in 10\/17 patients, and partially concordant in 3\/17 patients. New foci were identified in 4\/17 patients. The [<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup> conclusions influenced clinical shared decision-making in 15\/17 patients, of whom 7 patients underwent TSS and 8 refrained from TSS. One patient underwent TSS despite negative [<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup>, and one patient underwent additional imaging. Intraoperative findings corresponded with [<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup> in 5\/8 patients, and immunohistochemistry was positive in 5\/8 patients. The treatment goal was achieved in 7\/8 patients, and remission was achieved in 5\/7 patients in whom total resection was considered feasible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]FET-PET\/MRI<jats:sup>CR<\/jats:sup> can be of added value in the preoperative decision-making process for selected patients with difficult-to-localize prolactinoma (remnants), or patients lacking a substrate on conventional MRI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-024-01430-y","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:19:01Z","timestamp":1721737141000},"page":"614-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-0679","authenticated-orcid":false,"given":"Victoria R.","family":"van Trigt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontine E. H.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9194-9615","authenticated-orcid":false,"given":"Huangling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4956-4037","authenticated-orcid":false,"given":"Iris C. M.","family":"Pelsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9739-7515","authenticated-orcid":false,"given":"Marco J. T.","family":"Verstegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-921X","authenticated-orcid":false,"given":"Wouter R.","family":"van Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-5554","authenticated-orcid":false,"given":"Lenka M.","family":"Pereira Arias-Bouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-3594","authenticated-orcid":false,"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"3","key":"1430_CR1","first-page":"363","volume":"121","author":"JR Davis","year":"2001","unstructured":"Davis JR, Farrell WE, Clayton RN (2001) Pituit Tumours Reprod 121(3):363\u2013371","journal-title":"Pituit Tumours Reprod"},{"issue":"2","key":"1430_CR2","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"1430_CR3","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH et al (2020) Surgery as a viable Alternative First-Line treatment for Prolactinoma patients. A systematic review and Meta-analysis. J Clin Endocrinol Metab 105(3):e32\u201341","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1430_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","volume":"51","author":"S Noronha","year":"2016","unstructured":"Noronha S et al (2016) Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 51(2):205\u2013210","journal-title":"Endocrine"},{"key":"1430_CR5","doi-asserted-by":"crossref","unstructured":"Petersenn S et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol","DOI":"10.1038\/s41574-023-00886-5"},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","volume":"87","author":"PR Jethwa","year":"2016","unstructured":"Jethwa PR et al (2016) Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery Versus Medical Therapy in the management of Microprolactinoma in the United States. World Neurosurg 87:65\u201376","journal-title":"World Neurosurg"},{"issue":"2","key":"1430_CR7","first-page":"125","volume":"78","author":"CC Zygourakis","year":"2017","unstructured":"Zygourakis CC et al (2017) Cost-effectiveness analysis of Surgical versus Medical Treatment of Prolactinomas. J Neurol Surg B Skull Base 78(2):125\u2013131","journal-title":"J Neurol Surg B Skull Base"},{"issue":"5","key":"1430_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s007010200064","volume":"144","author":"P Kremer","year":"2002","unstructured":"Kremer P et al (2002) Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir (Wien) 144(5):433\u2013443","journal-title":"Acta Neurochir (Wien)"},{"issue":"5","key":"1430_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-16-0639","volume":"175","author":"O Koulouri","year":"2016","unstructured":"Koulouri O et al (2016) Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11\u00a0C-methionine PET co-registered with MRI. Eur J Endocrinol 175(5):485\u2013498","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1430_CR10","doi-asserted-by":"publisher","first-page":"M107","DOI":"10.1530\/EJE-15-0616","volume":"173","author":"O Koulouri","year":"2015","unstructured":"Koulouri O et al (2015) A role for 11\u00a0C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome. Eur J Endocrinol 173(4):M107\u2013M120","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1430_CR11","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2020.3.FOCUS2052","volume":"48","author":"WA Bashari","year":"2020","unstructured":"Bashari WA et al (2020) PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg Focus 48(6):E8","journal-title":"Neurosurg Focus"},{"issue":"4","key":"1430_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11102-022-01229-9","volume":"25","author":"WA Bashari","year":"2022","unstructured":"Bashari WA et al (2022) (11)C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. Pituitary 25(4):573\u2013586","journal-title":"Pituitary"},{"issue":"4","key":"1430_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11102-022-01230-2","volume":"25","author":"LEH Bakker","year":"2022","unstructured":"Bakker LEH et al (2022) Implementation of functional imaging using (11)C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary 25(4):587\u2013601","journal-title":"Pituitary"},{"issue":"4","key":"1430_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/RLU.0b013e3181d19098","volume":"35","author":"F Gemmel","year":"2010","unstructured":"Gemmel F et al (2010) Occult prolactinoma diagnosed by FDG PET\/CT. Clin Nucl Med 35(4):269\u2013270","journal-title":"Clin Nucl Med"},{"issue":"3\u20134","key":"1430_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.wneu.2013.11.011","volume":"82","author":"S Rodriguez-Barcelo","year":"2014","unstructured":"Rodriguez-Barcelo S et al (2014) Clinical usefulness of coregistered 11\u00a0C-methionine positron emission tomography\/3-T magnetic resonance imaging at the follow-up of acromegaly. World Neurosurg 82(3\u20134):468\u2013473","journal-title":"World Neurosurg"},{"issue":"3","key":"1430_CR16","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1097\/RLU.0000000000001085","volume":"41","author":"Z Feng","year":"2016","unstructured":"Feng Z et al (2016) Utility of 11\u00a0C-Methionine and 18F-FDG PET\/CT in patients with functioning pituitary adenomas. Clin Nucl Med 41(3):e130\u2013e134","journal-title":"Clin Nucl Med"},{"issue":"3\u20134","key":"1430_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000095529","volume":"83","author":"C Muhr","year":"2006","unstructured":"Muhr C (2006) Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology 83(3\u20134):205\u2013210","journal-title":"Neuroendocrinology"},{"issue":"7","key":"1430_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/BF00181283","volume":"18","author":"BJ Daemen","year":"1991","unstructured":"Daemen BJ et al (1991) PET studies with L-[1-11\u00a0C]tyrosine, L-[methyl-11\u00a0C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment. Eur J Nucl Med 18(7):453\u2013460","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"1430_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3171\/2014.10.JNS14911","volume":"122","author":"P Chittiboina","year":"2015","unstructured":"Chittiboina P et al (2015) High-resolution(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. J Neurosurg 122(4):791\u2013797","journal-title":"J Neurosurg"},{"issue":"4","key":"1430_CR20","first-page":"610","volume":"32","author":"M Bergstr\u00f6m","year":"1991","unstructured":"Bergstr\u00f6m M et al (1991) PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 32(4):610\u2013615","journal-title":"J Nucl Med"},{"key":"1430_CR21","doi-asserted-by":"crossref","unstructured":"Krakauer M, Kjaer A, Bennedb\u00e6k FN (2016) (18)F-FET-PET in primary hyperparathyroidism: a pilot study. Diagnostics (Basel), 6(3)","DOI":"10.3390\/diagnostics6030030"},{"issue":"1","key":"1430_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11307-019-01337-2","volume":"22","author":"LM Carter","year":"2020","unstructured":"Carter LM et al (2020) The impact of Positron Range on PET Resolution, evaluated with phantoms and PHITS Monte Carlo Simulations for Conventional and non-conventional radionuclides. Mol Imaging Biol 22(1):73\u201384","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"1430_CR23","first-page":"205","volume":"40","author":"HJ Wester","year":"1999","unstructured":"Wester HJ et al (1999) Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40(1):205\u2013212","journal-title":"J Nucl Med"},{"issue":"6","key":"1430_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s11102-021-01160-5","volume":"24","author":"S Berkmann","year":"2021","unstructured":"Berkmann S et al (2021) Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET\/MRI. Pituitary 24(6):878\u2013886","journal-title":"Pituitary"},{"key":"1430_CR25","doi-asserted-by":"crossref","unstructured":"Bakker L et al (2023) 18F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly","DOI":"10.21203\/rs.3.rs-3799944\/v1"},{"issue":"2","key":"1430_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1430_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1530\/EJE-19-0344","volume":"181","author":"DJ Lobatto","year":"2019","unstructured":"Lobatto DJ et al (2019) Toward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care. Eur J Endocrinol 181(4):375\u2013387","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1430_CR28","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/s00259-006-0206-3","volume":"33","author":"T Vander Borght","year":"2006","unstructured":"Vander Borght T et al (2006) EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 33(11):1374\u20131380","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1430_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10143-023-02033-0","volume":"46","author":"M Ottenhausen","year":"2023","unstructured":"Ottenhausen M et al (2023) Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients. Neurosurg Rev 46(1):128","journal-title":"Neurosurg Rev"},{"issue":"2","key":"1430_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00259-005-1882-0","volume":"33","author":"BN Tang","year":"2006","unstructured":"Tang BN et al (2006) 11\u00a0C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging 33(2):169\u2013178","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01430-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:56:05Z","timestamp":1730868965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01430-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01430-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"9 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest or funding details to disclose. The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}